Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03713632 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

545

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa

Interventions

DRUG: Secukinumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals